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Available online 18 March 2017Brief batteries in schizophrenia, are needed to screen for the cognitive impact of schizophrenia.We aimed to val-
idate and co-norm the Epidemiological Study of Cognitive Impairment in Schizophrenia (EPICOG-SCH) derived
brief cognitive battery. A cross-sectional outpatient evaluation was conducted of six-hundred-seventy-two pa-
tients recruited from 234 centers. The brief battery included well-known subtests available worldwide that
cover cognitive domains related to functional outcomes:WAIS-III-Letter-Number-Sequencing-LNS, Category Flu-
ency Test-CFT, Logical-Memory Immediate Recall-LM, and Digit-Symbol-Coding-DSC. CGI-SCH Severity and
WHO-DAS-S were used to assess clinical severity and functional impairment, respectively. Unit Composite
Score (UCS) and functional regression-weighted Composite Scores (FWCS) were obtained; discriminant proper-
ties of FWCS to identify patients with different levels of functional disability were analyzed using receiver-oper-
ating characteristic (ROC) technique. The battery showed good internal consistency, Cronbach's alpha = 0.78.
The differences between cognitive performance across CGI-SCH severity level subscales ranged from 0.5 to 1
SD. Discriminant capacity of the battery in identifying patients with up to moderate disability levels showed
fair discriminant accuracy with areas under the curve (AUC) N 0.70, p b 0.0001. An FWCS mean cut-off
score ≥ 100 showed likelihood ratios (LR) up to 4.7, with an LR+ of 2.3 and a LR− of 0.5. An FWCS cut-
off ≥ 96 provided the best balance between sensitivity (0.74) and speciﬁcity (0.62).
The EPICOG-SCH proved to be a useful brief tool to screen for the cognitive impact of schizophrenia, and its re-
gression-weighted Composite Score was an efﬁcient complement to clinical interviews for conﬁrming patients'
potential functional outcomes and can be useful for monitoring cognition during routine outpatient follow-up
visits.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cognitive impairment is one of the primary features of schizophre-
nia, and such impairment has an associated impact on patientJoint Mid-Year Meeting of the
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. This is an open access article underfunctioning in daily life (Bowie and Harvey, 2006; Bowie et al., 2008;
Green et al., 2000; Green et al., 2004a; Harvey et al., 2006a; Harvey et
al., 2006b; Velligan et al., 1997; Green, 1996; Velligan et al., 1997). Over-
all, cognition accounts for 20–60% of the variance in patients' functional
outcomes across studies (Galderisi et al., 2014; Velligan et al., 1997;
Zaragoza Domingo et al., 2015). On a practical level, it is currently
broadly accepted that functional capacity shows very strong and consis-
tent associations with performance on neurocognitive test batteries
(Green and Harvey, 2014; Harvey, 2012).
The cognitive impairment associatedwith schizophrenia is accepted,
including its wide variability and heterogeneity both, in the domains
that are affected and the degree to which these domains are involved
(Fioravanti et al., 2012). A large proportion, but not all, of schizophrenia
patients might develop signiﬁcant, moderate-to-severe cognitive im-
pairment (Montgomery and van Zwieten-Boot, 2007), however ap-
proximately 20–25% of patients might have normal scores on
neuropsychological tests (Lennertz et al., 2016; Palmer et al., 2009;
Wexler et al., 2009), consequently showing a substantial overlap ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of the ﬁrst published meta-analyses, based on the average patient per-
formance on 22 psychological tests, patient performance was between
0.46 and 1.41 SD below the performance of controls (Heinrichs and
Zakzanis, 1998), and the deﬁcit be as severe as 2–3 standard deviations
below the mean (Keefe et al., 2006).
Based on studies with different patient groups and different strate-
gies of analysis, the processing speed and, more recently,working memo-
ry domains have been recognized as valid and efﬁcient indicators of
overall cognitive functioning in schizophrenia that are also related to
functional outcomes (Hurford et al., 2011; Wong et al., 2013; Fervaha
et al., 2014a; Kern et al., 2011). In these published studies, subtests
such as letter sequencing (LNS), digit-symbol coding (DSC) and catego-
ry ﬂuencies subtest CFT) were identiﬁed as key subtests to be used in
schizophrenia. Somehow, these key subtests are linked to the most rel-
evant pathophysiological ﬁndings in the disease (Joyce, 2013).
Regarding cognitive assessment, the instruments typically used to
measure cognitive function in schizophrenia fall into threemain catego-
ries, with a high variation in their testing times: performance-based as-
sessment batteries comprising standard neuropsychological tests
(mostly paper and pencil), computerized performed-based test batte-
ries, and interview-based assessments (Keefe, 2012). Although perfor-
mance-based measures are essential for measuring cognitive change,
clinicians at the International Society for CNS Clinical Trials Methodolo-
gy (ISCTM) consensus meeting noted their cost and time requirements
as evidence of impracticality. Among the factors considered there were
the complexity of test administration, sensitivity and reliability, time,
cost, reimbursement, and training.
In this context, brief performance-based assessment batteries
are considered a real solution to cover evaluation needs in clinical
practice. Some brief (RBANS (Gold et al., 1999); BACS (Keefe et
al., 2004), SCIP-S (Pino et al., 2007; Purdon, 2005)) or ultra-brief
cognitive batteries with b4 subtests, such as the BNA (Fervaha et
al., 2014a), the BCA (Velligan et al., 2004), or the B-CATS (Hurford
et al., 2011), have been developed using different construct models
and are currently available for use in clinical contexts (Bakkour et
al., 2014; Keefe et al., 2016). The existing ultra-brief perfor-
mance-based cognitive measures were developed using data from
studies with large patient samples, suggesting that shorter tests
were equally sensitive. However, this approach offers little control
for study sample heterogeneity because the selection criteria have
various objectives; therefore, validation of this ultra brief measures
was performed using a sample recruited for various purposes.
In the Epidemiological Study of Cognitive Impairment in Schizo-
phrenia (EPICOG-SCH), we evaluated the performance of clinically
stable patients on speciﬁc cognitive domains proven to be associat-
ed with functional status as reported in the literature, and we esti-
mated the prevalence of cognitive impairment in those domains
and its relationship to patients' clinical features and functional out-
comes (Zaragoza Domingo et al., 2015). In this paper, we present
the validation data for this new performance-based assessment
battery, i.e., the EPICOG-SCH brief battery, co-norming the 4 differ-
ent subtests and standardizing the battery across a large of clinical-
ly stable sample of outpatients undergoing stable drug treatment
with second-generation antipsychotic drugs as their primary ther-
apy. Battery summary scores are presented emphasizing a func-
tional regression-weighted Composite Score (FWCS) with the
capacity to conﬁrm and predict functional disability related to a
patient's mental health condition.
This study will provide information to clinicians about the validity
and reliability of the new EPICOG-SCH brief battery, which is useful
not only to screen the cognitive status of schizophrenia outpatients
but also to monitor the cognitive impact of schizophrenia over time.
Normative data based on a large representative population are also pro-
vided and ready to use as a reference for mental health specialists in
clinical practice.2. Materials and methods
We conducted a cross-sectional epidemiological study with a sam-
ple of schizophrenia outpatients diagnosed according to the DSM-IV-
TR criteria (American Psychiatric Association, 2002)whowere onmain-
tenance treatment with at least one second-generation antipsychotic
drug and for whom all drug treatments had remained stable during
the previous six months. The patients attended a routine follow-up
visit at one of the community-based mental health service centers,
within the National Public Health System in Spain. A full description of
the methods and procedures for the study is given elsewhere
(Zaragoza Domingo et al., 2015). The participants completed informed
consent to participate in the study. The studywas approved by the Clin-
ical Research Ethics Committee of one of the participating centers, and
this approval extended to all the other sites.
2.1. Cognitive assessment battery
For the selection of the domains to be included, the MATRICS-RAND
reviewworkwas used to deﬁne the relationship to functional outcomes
(Nuechterlein et al., 2008; Green et al., 2004b). With the aims of creat-
ing an ad hoc brief instrument, not all 7 domains selected by MATRICS
panel were selected, but those domains more related to schizophrenia
as a minimal set and also aiming to capture the effect of common con-
comitant drug prescription practices (as it is frequently reported CNS
drug poly-therapy aswell theuse of concomitant anticholinergic agents,
among others). Subtests also were selected by considering a list of
criteria deﬁned a priori and sorted by priority, as described in Table 1,
theﬁnal composition of the batterywas based on these criteria. Four do-
mains were identiﬁed as relevant in schizophrenia, including executive
function (although it was not initially considered within the MATRICS
review model), and cognitive battery comprised four subtests: Letter-
Number Sequencing (LNS), Digit Symbol Coding (DSC), Logical Memory
(LM), and the Category Fluency Test (CFT). A full description of the test-
ing procedures is provided elsewhere (Zaragoza Domingo et al., 2015).
The relationship between cognitive subtests and functional outcomes
was based on a previously published review (Nuechterlein et al.,
2008): the review reported that performance on LNS subtest showed
an association with the capacity to have a work contract in two studies
including patients with severe mental disease (Study 1, N = 33, r =
0.48, p b 0.001, and Study 2, N = 40, r = 0.38, p b 0.05); performance
on LM was also associated with the capacity to have a work contract
in patients diagnosed with severe mental disorder (r = 0.4, p b 0.05)
and was related to quality of life in a sample of patients with schizo-
phrenia (r = 0.37, p = 0.04); performance on the CFT (4 categories)
was not related to having a work contract (r = 0.44, non-signiﬁcant)
but was associated with quality of life in patients with schizophrenia
(r = 0.54, p b 0.001); and performance on the DSC subtest in a sample
of healthy adults was associated with measures of vocational outcome
(r = 0.42, p b 0.001).
2.2. Data analysis
All forms were centrally collected, and the scores for cognitive tests
were centrally monitored to check for accuracy and consistency among
the raters.
For the impairment prevalence estimates, raw scores were trans-
formed into standardized scores (scalar or centile depending on the
test) based on published local normative data (Wechsler, 2001;
Casals-Coll et al., 2013; Pena-Casanova et al., 2009), with age as the
only stratiﬁcation variable (CFT-Animals) and age and years of educa-
tion for the other subtests. The prevalence of impairment was deﬁned
as the percentage of patients with scores below the cut-off, which was
equal to or b1.5 standard deviations (SD) from the mean of standard-
ized scores (i.e., a−1.5 SD cut-off, corresponding to a score b 5.5 for
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at all cut-off values by gender are described.
The battery summary Composite Scores were calculated using unit-
and regression-weighted based models, UCS and FWCS respectively
(see Table 1 for exact standardization and calculation process). The
FWCS was based on a regression analysis in which standard scores
were weighted based on their contribution to a patient's functional sta-
tus according to theWHO-DAS-S. To improve the percentage of variabil-
ity explained only by cognitive performance, a new WHO-DAS-S Total
Score termed the WHO-DAS-SF was calculated per patient as the total
number of unaffected domains according to the WHO-DAS-S; i.e., for
each patient, the number of domains on the WHO-DAS-S with a
score b 2 corresponding to “Non-disability or minimal disability” was
calculated. This newmeasure ranged from 0 to 4, 4 representing no dis-
ability (i.e., all 4 domainswere unaffected), and 0 representingdisability
in all 4 domains (i.e., meaning 0 domains were unaffected). A linear re-
gression analysis was built withWHO-DAS-SF where cognitive subtests
were predictive variables, and a stepwise method for factor inclusion
was used to determine weights (β) for each cognitive subtest.
The internal consistency and criterion validity of the battery were
calculated. The criterion validity of the battery was based on the rela-
tionship between the Composite Scores and the patients' clinical and
functional status. The Wilcoxon test was used to describe differences
in performance among clinical subgroups, and Pearson and Spearman
correlations were used to describe the association between cognitive
performance and clinical and functional disability results. Patients at
each level of symptom severity were compared following the categori-
zation of severity, and patients in the symptom “Not Present” category
were comparedwith those in the other ill-deﬁned “categories” grouped
into a single category. This method was used to smooth differences in
cognitive performance on each symptom subscale between extreme se-
verity levels.
For group differences, we also present Cohen's d as a measure of the
standardized effect size (SES). A stepwise multiple linear regression
analysis was used to explore the relationship between cognitive perfor-
mance (each subtest and each Composite Score) and factors related to
the natural course of the disease, usingnatural factors as dependent var-
iables. The factors considered here were Years of Disease Evolution i.e.,
elapsed time since ﬁrst episode, Age at First Episode, Number of Relapses
during the Previous Year, Elapsed Time since Last Relapse, Genderwas also
included in all regression models.
To further explore the utility for both Composite Scores for
predicting a patient's functional status, the Composite Score with better
discriminative properties based on receiver operating characteristic
(ROC) analysis was selected, and a cut-off score was calculated accord-
ing to its capacity to discriminate between levels of the patient function-
ality-disability under different deﬁnitions (see Table 1 and
Supplementary Table 1). All statistical tests were performed with the
signiﬁcance level set at 5%. The data were analyzed using SAS software
(SAS Institute, Cary, NC).
3. Results
Of 848 patients from 234 centers, 672 were analyzed; 176 cases
(20.8%)with protocol deviationswere identiﬁed, primarily due to an in-
sufﬁcient maintenance treatment duration or a drug regimen change (a
detailed sample description can be found elsewhere (Zaragoza
Domingo et al., 2015). The prevalence of cognitive impact varied accord-
ing to the method used, ranging from 78% in patients' responses to an
open question, to 91% when considering clinician impression scales
(Haro et al., 2003). Ultimately, cognitive impairment based on objective
measurement varied, depending on the subtest, from a prevalence of
20.9% for DSC to 65.8% for CFT.
Men andwomen showed similar cognitive results across all subtests
and Composite Scores, and only small differences were observed; men
showed better performance on LNS and CFT, while women showedbetter performance on LM-Issues. In addition, an analysis of gender dif-
ferences in the prevalence of impairment at a cut-off of 1.5 SD showed
highly similar rates for men and women (see Table 2), and at a less se-
vere impairment (cut-off− 1 SD), fewer women thanmen showed im-
pairment on Verbal Memory and Information Processing Speed, i.e., LM
Items (p = 0.019), Issues (p = 0.003) and DSC (p = 0.024). Also less
women were at severe impairment group (cut-off of−2 SD) for Verbal
Memory, LM Item subtest (p = 0.034).
The descriptive statistics obtained following the calculation of the
summary Composite Scores UCS and FWCS are included in Table 1.
We found a signiﬁcant overall effect of age, level of education and func-
tional status, on all individual subtests and on the Composite Scores
(Table 3). Higher education, younger age and an active functional status
were associated with better cognitive performance.
3.1. Battery properties and criterion validity
The internal consistency of the battery was demonstrated by a
Cronbach's alpha score of 0.78, indicating good internal consistency
among subtests.
The criterion validity analysis showed a moderate and statistically
signiﬁcant relationship between the patients' performance on the cog-
nitive battery results and their overall clinical status based on the clini-
cal impression scales (Table 4), battery Composite Scores showed a
modest inverted linear relationshipwith the severity of Cognitive Symp-
toms (r = −0.44, p b 0.001) and also with severity of Global Disease
(r = 0.40, p b 0.001) and Negative Symptoms (r =−0.28, p b 0.001).
This association was further explored by comparing the performance
of patients within severity levels ﬁrst at the subtests level and subse-
quently at the Composite Scores level (Fig. 1). First, as for the individual
subtests, the severity of Negative Symptoms and Global Disease was
largely associated with a decreased performance on Memory/Working
Memory subtests: Negative Symptoms severity was associated with LM
(p b 0.0001) and LNS (p b 0.0001) and Global Disease severitywas asso-
ciated with LM (p b 0.0021). Furthermore, the severity of Positive Symp-
toms was associated with decreased performance on the Information
Processing Speed subtest, DSC (p b 0.0001). To a lesser extent but still
signiﬁcantly, we found that patients with associated Deﬁcit Syndrome
performedpoorly, withmoderate differences onMemory and Executive
subtests; LNS (p b 0.0001), LM (p b 0.0001) and CFT (p b 0.0001). Final-
ly, the severity of Depressive Symptoms, was associated with the perfor-
mance in all subtests, but predominantly to the Information Processing
Speed task DSC (p= 0.0008). It is important to highlight the strong as-
sociation observed betweenDSC and CFT subtests (r=0.57, p=0.001),
which suggests that the DSC makes a moderate contribution to execu-
tive functioning domain.
Looking at the battery Composite Scores, for all symptom subscales
the mean score differences of UCS and FWCS across severity categories
ranged from 0.5 to 1 SD below the mean, with the exception of the De-
pressive Symptomswhich showed a smaller effect. Similar to the results
for the subtests, the Composite Scores, showed the largest effect for the
performance and severity of Global Disease and Negative Symptom se-
verity, followed by amedium to large effect for the presence of associat-
ed Deﬁcit Syndrome, a medium effect for the severity of Positive
Symptoms severity, and a small effect for severity of Depressive
Symptoms.
For each symptom subscale the following differences in mean scor-
ing were obtained; for the Negative Symptoms subscale, the UCS mean
score difference was −11.6, SD 14.7, 95% CI (−15.5 to −7.7),
p b 0.0001, and the FWCS mean difference was−11.2, SD 14.7, 95% CI
(−15.1 to−7.2), p b 0.0001. For the Global Severity subscale, the UCS
mean difference was −11.4, SD 14.8, 95% CI (−16.8 to −6.0),
p b 0.0001, and the FWCS mean difference was−9.9, SD 14.9, 95% CI
(−15.3 to −4.4), p b 0.0001. For the Positive Symptoms subscale, for
UCS, the mean difference was−7.9, SD 14.7, 95% CI (−10.5 to−5.3),
p b 0.0001, and for FWCS, the mean difference was−8.1, SD 14.6, 95%
Table 1
The EPICOG-SCH brief cognitive battery: development and derived scores.
Set of Criteria Used to Select Subtests
For the ﬁnal composition of the EPICOG-SCH battery, a list of criteria was elaborated to guide the selection of cognitive subtests. Subtest candidates should be in line with as
many criteria as possible, with criteria 1 to 5 taken as priority and criteria 6 to 9 taken to guide the selection when there are several options.
1. Subtest evaluating domains related to functional measures in the disease.a
2. Subtests evaluating any of the domains relevant to the disease supported by literature.
3. Subtest easy to administer without the need for special training.
4. Demonstrated sensitivity in pharmacological studies.a
5. Demonstrated stability over time (very small test-retest variation).a,b
6. Availability of local versions and normative data from the general population, published whenever possible.
7. Subtests allowing extracting conclusions related to the disease (not simplistic).
8. Subtests with strategic interest for future research.
9. Potential to be part of a battery and co-normative data on the target population.
Ad hoc cognitive subtests selected and the corresponding classical domains
[Mean estimated administration time: 20 to 30 minutes]
Subtestc Domain Contribution Average Administration Time (min.)
• LNS, Letter Number Sequencing - WAIS-III (Weschler D, 2001; Gold et al., 1997) Working memory 5-15
• CFT, Category Fluency Test (3 categories: animals, fruits, and cities/villages)
(Benton A.L and Hamscher., 1978)
Speed of Information Processing
Executive functioning
5
• DSC, Symbol-Digit Coding - WAIS-III (Weschler D, 2001)
Speed of information processing
Working memory
5
• LM, Logical Memory WMS-III - Text A (Wechsler D, 2001) Verbal memory 6-10
Composite Scores
• Unit Total Composite Score (UCS) • Raw data from subtests were ﬁrst transformed into standard Z scores and then
transformed into scalar scores, with mean 10 SD 3. Subtest scalar scores were
added, and the result was transformed into Z scores, followed by transformation
into the UCS, with mean 100 and SD 15, resulting in a 95% CI of 98.8 to 101.1 and
ranging from 53.6 to 152.9; test for normality p b 0.005.
• Functional Weighted Composite Score (FWCS) • Raw subtest scores were transformed into Z scores, and then each subtest score is
weighted using β values and summed using a regression equationd. Resulting
values were ﬁrst standardized into Z scores and then transformed to the FWCS,
with mean 100 and SD 15, resulting in a 95% CI of 98.9 to 101.1, ranging from 60.7
to 159.8; test for normality p = 0.070.
Cut-off Scores for composite scores
• Impact on Global Functioninge Cut-off score based on Comopsite Scores able to predict patient functional outcome.
For FWCS a mean cut-off score ≥ 100 increase the probability of correctly identifying
patients with no or moderate functional impact by up to 4.7 times, and FWCS
cut-off ≥ 96 provided the best balance between sensitivity (0.74) and speciﬁcity (0.62).
Normative Data
• Subtest and Composite Scores Tabulated data from the normative study population (clinically stable), without
adjustments, to facilitate the conversion from row to percentile scores as mean
group values (see Supplementary tables 2-6).
The aim of developing the EPICOG-SCHwas to create a brieﬂy administered battery, i.e., requiring less than 30minutes, to be included in clinical practice protocols for schizophrenia out-
patient follow-up visits. Method for initial test selection by setting a priori criteria as a ﬁrst stepwas similar to the MATRICS initiative process of developing a consensus battery (Green et
al., 2004). EPICOG-SCH battery, based in classical well known neuropsychological tests, is easy to administer in a standardized procedure bymental health professionals and is suitable for
evaluating any type of patient who is able to cooperate and understand.
a Based on review data from the MATRICS group (Nuechterlein et al., 2008).
b According to published rest-retest properties (McCaffrey R.J., 2000).
c The relationship between cognitive subtests and functional outcomes was based on previously published information (Nuechterlein et al., 2008).
d The FWCS was based on a regression analysis in which standard scores were weighted by their contribution to a patient´s functional status according to WHO-DAS-S From this re-
gressionmodel, cognitive performance alone explained 17.4% of the patients’ functional status (WHO-DAS-SF (p= 0.000)), including LNS p= 0.000, CFT, p = 0.001, DSC p= 0.037, LM
Items p = 0.289 (ns) and LM Issues p = 0.810 (ns).
e ROC analysiswas applied to testmodels of functionality or disability according to pre-deﬁned categories based onWHO-DAS-S scores for eachdimension (see Supplementary Table 1).
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the largest mean difference was for FWCSwhich showed amean differ-
ence of−4.0, SD 14.9, 95% CI (−6.3 to−1.6), p = 0.0010.
Fig. 2 shows performance results for FWCS for each individual sever-
ity category for clinical impression subscales, illustrating the observed
associations. With the aim of exploring other categorization strategies
to enhance differences, i.e., instead grouping categories, for each sub-
scale comparing the patients within two extreme severity categories
(those Normal vsMarkedly Ill). With this strategy we found even stron-
ger effects on FWCS results, i.e., the SES results for the severity ofCognitive Symptom it was 1.41, for severity of Global Disease it was
1.20, for severity ofNegative Symptom it was 1.18, for severity ofDepres-
sive Symptom it was 0.76, and for severity of Positive Symptom it was
0.72.
For factors related to the natural course of the disease, we observed
only one factor, Years of Disease Evolution, which was inversely related
to cognitive performance and had weak correlations with subtest per-
formance and being with Information Processing Speed (DSC) the
greatest one (r =−0.22, p b 0.001) (see Table 4). Regression analysis
allowed us to further explore these relationship, and revealed for all
Table 2
Cognitive performance results of the EPICOG-SCH brief battery subtests and the prevalence of cognitive impairment by total sample and by gender.
Cognitive performancea Prevalence of cognitive impairment Gender differences
Cognitive Subtest and
Derived Scores
Total sample
(N = 672)
Male
(N = 447)
Female
(N = 218)
p SES
Total sample
(N = 672)
Male
(N = 447)
Female
(N = 218)
Prevalence of Cognitive
Impairment at
≤1.5 SD Cut-off
Mean SD Mean SD Mean SD ≤1 SD
(Score ≤ 7)
≤1.5 SD
(Score ≤ 5.5)
≤2 SD
(Score ≤ 4)
≤1 SD
(Score ≤ 7)
≤1.5 SD
(Score ≤ 5.5)
≤2 SD
(Score ≤ 4)
≤1 SD
(Score ≤ 7)
≤1,5 SD
(Score ≤5.5)
≤2 SD
(Score ≤ 4)
p
Letter-Number
Sequencing
(WAIS-III)
8.5 3.9 8.8 4.0 8.0 3.7 0.008 −0.21 37.7 20.9 12.8 36.8 20.4 12.7 39.9 22.1 13.0 ns
Digit-Symbol Coding
(WAIS-III)
43.6 21.5 43.6 21.0 43.4 22.6 ns – 63.4 38.1 27.9 65.4 38.9 29.0 59.5 36.2 25.7 ns
Logical Memory
(WMS-III-Text A)
Units 10.4 4.6 10.2 4.6 10.9 4.6 ns – 38.0 24.8 12.2 40.3 25.5 13.7 33.8 23.8 9.2 ns
Issues 4.6 1.7 4.4 1.7 4.9 1.6 0.002 0.25 25.4 11.7 6.0 28.7 13.7 6.7 19.2 8.1 4.8 0.004
≤25th
percentile
≤10th
percentile
≤5th
percentile
≤25th
percentile
≤10th
percentile
≤5th
percentile
≤25th
percentile
≤10th
percentile
≤5th
percentile
Category ﬂuency test 39.4 15.6 40.2 15.2 37.9 16.4 0.045 −0.15 – – – – – – – – – –
Animalsb 14.0 5.6 14.2 5.7 13.5 5.8 ns – 82.5 65.8 57.8 81.9 64.6 56.3 83.7 67.8 60.9 ns
Fruitsc 10.0 3.6 10.0 3.4 10.0 3.8 ns – – – – – – – – – – –
Cities-Villagesc 15.5 8.1 16.0 8.0 14.4 8.4 0.017 −0.20 – – – – – – – – – –
SD, standard deviation; SES, standardized effect size (Cohen's d), interpretation Small 0.20, Medium 0.50, Large 0.80.
Prevalence of cognitive impairment is based on population normative data available in the country for each individual subtest. In a normal distribution, the expected percentages of patients performing at ≤1 SD andof patients performing at ≤2 SD cut-
offs are 15.7% and 2.1%, respectively. Disability in cognitive tests was set at ≤1.5 SD (10th percentile). Estimates for the cut-offs of 1.0 (25th percentile) and 2.0 SD (5th percentile) below the mean are also included, and they correspond to the lower
limit of normal cognitive performance and to severe impairment, respectively (Harvey et al., 2006b; Taylor and Heaton, 2001); these cut-offs for scalar scores correspond to scores between b7 and b4 and for centile scores between b25 and b5,
respectively.
a Raw Scores.
b Spanish normative value available CFT-Animals, from the Neuronorma project; for young population (Casals-Coll et al., 2013) and for older population (Pena-Casanova et al., 2009). Estimated prevalence adjusted by both age and years of ed-
ucation achieved (N = 640).
c Normative data not available in Spain.
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Table 3
EPICOG-SCH battery composite scores relationship to sociodemographic, clinical and functional factors.
Variable Unit Composite Score (UCS) Functional Weighted Composite Score (FWCS)
Differencea 95% CI
Difference
Differencea 95% CI
Difference
.
n Mean SD Mean Low High Sign. SES Mean SD Mean Low High Sign SES
Sociodemographic
Age range (years)
18–39 335 102.3 14.3 −10.2 −14.1 −6.2 b0.0001 −0.66 102.3 14.2 −9.8 −13.7 −5.8 b0.0001 −0.66
40–49 186 100.5 14.2 100.2 14.8
50–69 95 92.2 15.6 92.6 15.1
Gender
Male 446 99.8 14.7 0.2 −2.2 2.3 0.8114 −0.11 100.7 14.8 −2.3 −4.7 0.1 0.061 ns −0.15
Female 216 100.0 15.7 98.4 15.2
Level of education
No education completed 66 84.6 14.7 24.4 18.6 30.9 b0.0001 1.76 84.8 12.7 23.8 17.6 30.1 b0.0001 1.78
Primary 312 96.9 13.6 97.2 13.6
High school 226 106.1 12.6 106.0 13.4
University 60 109.4 13.5 108.6 14.2
Clinical proﬁle
Deﬁcit syndromeb
No 453 106.6 13.9 −9.8 −12.2 −7.4 b0.0001 −0.69 106.7 14.6 −9.9 −12.3 −7.6 b0.0001 −0.69
Yes 209 96.8 14.5 96.8 14.1
Treatment-related measures
Treatment adherence
Yes 542 100.8 14.7 −4.7 −7.8 −1.6 0.0041 −0.32 101.2 14.8 −6.0 −9.1 −2.9 0.0002 −0.41
No 103 96.1 15.1 95.2 14.6
Anticholinergic agents
No 567 100.9 14.8 −6.3 −9.4 −3.1 0.0002 −0.42 100.7 14.9 −4.3 −7.4 −1.2 0.0059 0.29
Yes 105 94.7 15.2 96.4 15.3
Treatment satisfactionc
Not at all 7 97.6 23.1 13.1 5.4 20.5 b0.0001 0.81 97.5 20.4 13.3 5.8 20.8 b0.0001 0.84
Slightly satisﬁedc 69 90.5 16.5 90.8 15.3
Moderately satisﬁed 172 98.6 12.6 97.9 12.9
Very satisﬁed 370 102.1 14.8 102.5 14.7
Extremely satisﬁedc 48 103.5 15.7 104.1 16.2
Functional measures
Occupational status
Non-active 417 97.8 14.9 7.2 5.0 10.1 b0.001 0.51 98.4 14.8 5.6 3.3 8.4 b0.0001 0.39
Active 204 105.3 14.6 104.3 15.2
Currently a student
No 569 98.4 14.6 12.7 9.3 16.1 b0.001 0.92 98.6 14.5 11.6 8.2 15.0 b0.0001 0.80
Yes 80 111.0 12.8 110.1 14.4
Type of work
Non-qualiﬁed worker 121 102.0 14.3 7.2 0.0 14.3 0.071 ns 0.46 101.6 13.8 8.5 1.4 15.6 0.0115 0.59
Qualiﬁed worker 54 103.5 11.1 104.9 11.9
Qualiﬁed professional 25 109.1 16.2 110.1 15.7
WHO DAS-S Disability personal care
No 473 103.4 13.8 −11.8 −14.1 −9.5 b0.001 −0.82 103.9 13.7 −13.3 −15.5 −11.0 b0.001 −0.96
Yes 198 91.6 13.0 90.6 13.9
WHO DAS-S Disability occupational
functioning
No 195 105.9 13.4 −8.4 −10.8 −5.9 b0.001 −0.59 106.4 13.8 −9.0 −11.4 −6.6 b0.001 −0.56
Yes 474 97.5 15.0 97.4 14.7
WHO DAS-S Disability familiar functioning
No 257 105.2 13.4 −8.4 −10.6 −6.1 b0.001 −0.59 105.5 13.5 −8.8 −11.1 −6.1 b0.001 −0.63
Yes 413 96.8 15.0 96.6 14.9
WHO DAS-S Disability broad social
context
No 153 106.9 13.7 −9.0 −11.5 −6.3 b0.001 −0.69 107.3 13.9 −9.5 −12.0 −6.9 b0.001 −0.67
Yes 518 97.9 14.8 97.8 14.6
WHO-DAS-S Length of disability
Less than one year 48 106.5 16.0 −8.0 −12.8 −3.5 b0.001 −0.51 106.2 16.7 −7.6 −12.0 −3.2 0.0029 −0.48
One year or longer 534 98.7 14.9 98.7 14.7
WHO DAS-S Speciﬁc skills
No 503 99.0 15.2 3.7 1.1 6.3 0.0032 0.25 99.1 15.2 3.4 0.8 6.0 0.0078 0.24
Yes 169 102.7 14.1 102.6 14.2
Statistical signiﬁcance: *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001, SES, standardized effect size (Cohen's d), effect size interpretation, Cohen's d, small 0.20, medium 0.50, large 0.80.
WHO DAS-S, World Health Organization Disability Scale-Short Version (Janca et al., 1996; Sartorius et al., 1986).
a For multiple categories, overall signiﬁcance is reported but the mean difference, 95% IC and SES for the extreme categories are reported.
b According to speciﬁc criteria for deﬁcit syndrome (Arango et al., 1998; Arango et al., 2004; Kirkpatrick et al., 2000)
c For treatment satisfaction, the lowest signiﬁcant difference is reported, and the mean differences across categories ranged between 1.0 and 13.0 points.
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Table 4
Relationship between clinical impression symptoms severity, disability and cognitive results in the EPICOG-SCH battery.
Measure (N = 672) LNS CFT DSC LM-Items LM-Issues EPICOG-SCH Battery Composite Scores
Unit Sum (UCS) Functional Weighted (FWCS)
r r r r r r r
Clinical Evolution
Age of onset −0.01 −0.05 −0.09⁎ 0.01 −0.00 −0.06 −0.03
Time of evolution (years) −0.18⁎⁎⁎ −0.08⁎ −0.22⁎⁎⁎ −0.15⁎⁎⁎ −0.08⁎ −0.16⁎⁎ −0.17⁎⁎
Relapses during last year (#) −0.06 −0.03 0.05 −0.02 0.05 −0.02 −0.07
CGI – Severity
Global severity −0.36⁎⁎⁎ −0.26⁎⁎⁎ −0.32⁎⁎⁎ −0.32⁎⁎⁎ −0.25⁎⁎⁎ −0.40⁎⁎⁎ −0.40⁎⁎⁎
Cognitive symptoms −0.37⁎⁎⁎ −0.34⁎⁎⁎ −0.33⁎⁎⁎ −0.32⁎⁎⁎ −0.25⁎⁎⁎ −0.44⁎⁎⁎ −0.44⁎⁎⁎
Positive symptoms −0.21⁎⁎⁎ −0.15⁎⁎ −0.17⁎⁎⁎ −0.12⁎⁎ −0.10⁎ −0.21⁎⁎⁎ −0.23⁎⁎⁎
Negative symptoms −0.34⁎⁎⁎ −0.26⁎⁎⁎ −0.28⁎⁎⁎ −0.33⁎⁎⁎ −0.26⁎⁎⁎ −0.40⁎⁎⁎ −0.38⁎⁎⁎
Depressive symptoms −0.17⁎⁎⁎ −0.14⁎⁎ −0.17⁎⁎⁎ −0.04 −0.01 −0.14⁎⁎ −0.18⁎⁎
WHO-DAS-S Total Sum Score −0.38⁎⁎⁎ −0.33⁎⁎⁎ −0.31⁎⁎⁎ −0.28⁎⁎⁎ −0.20⁎⁎⁎ −0.41⁎⁎⁎ −0.44⁎⁎⁎
Personal care −0.35⁎⁎⁎ −0.31⁎⁎⁎ −0.27⁎⁎⁎ −0.23⁎⁎⁎ −0.14⁎⁎ −0.36⁎⁎⁎ −0.40⁎⁎⁎
Family and household −0.29⁎⁎⁎ −0.27⁎⁎⁎ −0.26⁎⁎⁎ −0.22⁎⁎⁎ −0.13⁎⁎ −0.32⁎⁎⁎ −0.35⁎⁎⁎
Occupational functioning −0.29⁎⁎⁎ −0.25⁎⁎⁎ −0.23⁎⁎⁎ −0.23⁎⁎⁎ −0.19⁎⁎⁎ −0.33⁎⁎⁎ −0.33⁎⁎⁎
Functioning on broader social context −0.31⁎⁎⁎ −0.28⁎⁎⁎ −0.22⁎⁎⁎ −0.25⁎⁎⁎ −0.19⁎⁎⁎ −0.35⁎⁎⁎ −0.36⁎⁎⁎
LNS, Letter-Number-Sequencing; CFT, Category Fluency Test; LM-Items, Logical-Memory Immediate Recall for Items; LM-Issues, Logical-Memory Immediate Recall for Issues; DSC, Digit-Symbol-Coding.
Stepwise multiple regression analysis included all variables related to disease course-related factors and gender, analyzing the contribution of these factors on subtypes and global composite scores for each patient's performance.
For FWCS, the resultingmodel for themultiple regression analysis (R2= 0.06 p b 0.0001) included years of disease evolution (β=−0.35, p b 0.0001), number of relapses during previous year (β=−1.64, p= 0.004), and age at ﬁrst episode, which
was not signiﬁcant (β=−0.154, p=0.143). Similarly, for UCS, the resultingmodel (R2=0.06, p b 0.001), included the same factors, i.e., years of disease evolution (β=−0.31, p=0.0001), number of relapses during previous year (β=−1.43, p=
0.0100).
For the subtests, for LNS, themodel (R2= 0.06, p b 0.0001) included years of disease evolution (β=−0.06, p b 0.0001), number of relapses during previous year (β=−0.30, p= 0.007), and gender, whichwas not signiﬁcant (β=0.49, p=0.076).
For DSC, themodel (R2=0.06, p b 0.0001) included years of disease evolution (β=−0.07, p b 0.0001), age at onset (β=−0.06, p=0.001), and number of relapses during previous year (β=−0.18, p=0.095). Overall, the correlation between age
at onset and years of disease evolution was r =−0.22, p b 0.0001.
For LM items, the model (R2 = 0.05, p b 0.0001) included years of disease evolution (β=−0.05, p = 0.0001), number of relapses during previous year (β=−0.27, p = 0.020) and gender, which was not signiﬁcant (β=−0.50, p = 0.077).
For LM issues, the model (R2 = 0.02, p = 0.005) included gender (β=−0.73, p = 0.008) and number of relapses during previous year (β=−0.01, p = 0.072), which was not signiﬁcant.
For CFT, the model (R2 = 0.02, p b 0.0001) included years of disease evolution (β=−0.035, p = 0.015), also but not signiﬁcant number of relapses during previous year (β=−0.022, p = 0.061) and age at onset (β=−0.038, p b 0.085).
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.
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Fig. 1. Standardized effect sizes (SES) by subtest and Composite Scores according to the patients' clinical proﬁle symptom severity. For each EPICOG-SCHmeasure, patients at each level of
symptom severity were compared following categorization of severitywhere those subjects at “Not Present” categorywere compared versus subjects at the all other ill-deﬁned categories”
grouped in a single category. SES values obtained from other published sources comparing healthy control groups and schizophrenia patient groups can be used as a reference to better
understand the comparison of performance across schizophrenia patients having different clinical proﬁles. Commonly, negative or positive SES value depends on how the author has
reported the comparison, but it consistently indicates impairment in the schizophrenia group compared to the healthy control group. The oldest meta-analysis reported a mean SES
for Global Verbal Memory subtests d = 1.41 and for Word Fluency d = 1.15, reporting 22 SES values from 204 studies to index schizophrenia versus control groups (Heinrichs and
Zakzanis, 1998). Subsequent results showed Hedge's g for DSC g =−1.55, Category Fluency g =−1.21, LNS g =−1.02 and Story Memory g =−1.41, with data from 100 studies
including healthy controls and 9048 people with schizophrenia (Schaefer et al., 2013)). More recently, results have been reported for Letter-Number Sequencing d = −0.95 and
Verbal Capacity d = −0.89, and the average SES for all Memory Tasks d = −0.95 was reported by comparing the relative size of group effects with 1101 healthy controls and 58
schizophrenia patients (Haut et al., 2015).
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and natural course factors (Table 4); for both Composite Scores the
resulting regression models included Years of Disease Evolution and
Number of Past Year Relapses, and for the individual subtests the same
two factors were related to the performance on Memory/WorkingFig. 2. Relationship in the EPICOG-SCH between FWCS results and CGI-SCH symptom severity su
severity on CGI-SCH subscales. FWCS scores are signiﬁcantly related to symptom severity: morMemory subtests (LNS and LM Items). The same two factors plus Age at
Onset were signiﬁcantly related to the performance on Information Pro-
cessing Speed (DST). For Memory (LM-Issues) signiﬁcant contributors to
the model where Number of Relapses during the Past Year and Gender; for
CFT performance only Years of Disease Evolution contributed signiﬁcantly.bscales. Battery EPICOG-SCH, composite score FWCSmean and 95% CI for each category of
e ill patients show lower cognitive performance as measured by FWCS scores.
Fig. 3. ROC curves to identify functional-disability status based on different diagnostic tools. ROC Receiver Operating Characteristics, FWCS Functional regression-Weighted Composite
Score, AUC, Area under the Curve. Fig. 3a ROC curves to identify functional outcomes based on cognitive testing from EPICOG-SCH brief battery FWCS. Only models with AUC results
≥0.70 are presented. An area of 1 represents a perfect test; an area of 0.5 represents a worthless test. Classiﬁcation of the accuracy of a diagnostic test according to AUC: 0.5 = No
Discrimination, 0.6–0.7 Poor, 0.7–0.8 Acceptable (fair), 0.8–0.9 Excellent (good) N 0.9 Outstanding. Fig. 3b ROC curves to identify functional outcome based on Clinician Impression
scale CGI-SCH Cognitive Subscale (Haro et al., 2003) considering all information available from patient's open question and cognitive testing from individual subtests performance.
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Patientswhowere activelyworking or engaged in types ofwork that
required greater qualiﬁcations obtained signiﬁcantly higher EPICOG-
SCH battery scores (see Table 3). Performance on the battery as mea-
sured by UCS and FWCS was inversely and moderately associated with
the level of functional disability assessed with the WHO-DAS-S. The
strongest relationship was found between cognitive performance and
Disability on Personal Care, followed by Disability on Social Functioning.
We also observed that patients with disability lasting longer than oneyear performed nearly−0.5 SDworse than thosewith disability lasting
less than one year.
Based on ROC analysis, compared with the UCS, the FWCS provided
more accurate diagnostic results in distinguishingmoderately function-
al patients under different models (see Supplementary Table 1), i.e. the
FWCS showed fair discrimination accuracy values with areas under the
curve (AUC) N 0.70 in identifying no functional-disability status under
different models tested (see Fig. 3). In the Personal Care dimension,
the model to identify no disability performed the best, resulting in an
AUC = 0.75, 95% CI 0.71 to 0.79; followed by the model to identify
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to 2 domains), with an AUC= 0.70, 95% CI 0.66 to 0.74; and ﬁnally the
model to identify patients deﬁnedwith lowdisability (none or disability
in just 1 domain), with an AUC = 0.71, 95% CI 0.66 to 0.76.
At an FWCSmean score of 100, the discrimination power represent-
ed by the likelihood ratio (i.e., diagnostic odds) ranged between 3.7 and
4.7 depending on themodel tested, indicating that following the admin-
istration of the battery, a cut-off ≥ 100 would increase the probability of
correctly identifying patients with no or moderate functional impact by
up to 4.7 times. Moreover, the conﬁrmatory power of the battery exhib-
ited low but interesting discriminative properties, as shown by the pos-
itive and negative likelihood ratios of LR+ ranging from 1.7 to 2.3 and
LR− from 0.4 to 0.5. This result indicates that a positive cognitive test
was found among moderately functional patients up to 2.3 times more
often than among patients with more severe impaired functionality
and that a negative result in the battery decreases the possibility of hav-
ing only moderate functionality impact by up to 0.5 times (and in-
creases the possibility of having more severe disability by up to 0.5
times).
Regarding the sensitivity and speciﬁcity, the results showed good
sensitivity, but low speciﬁcity, at speciﬁc cut-off scores. The best balance
between both indexes was found at an FWCS cut-off score of 96, i.e., b
0.5 SD below the mean, at which the sensitivity ranged from 0.72 to
0.74 and the speciﬁcity ranged from 0.56 to 0.62 depending on the
model tested; as the obtained FWCS scores decreased, the speciﬁcity
progressively decreased.
4. Discussion
The brief battery EPICOG-SCH is based on 4 subtests demonstrated
to be key in schizophrenia, and it has proven useful for screening to de-
termine for the cognitive impact of schizophrenia in clinically stable
outpatients. This battery showed good internal consistency, and the de-
rived Composite Scores showed a relationship with patient
sociodemographic proﬁle and as well as association with clinical fea-
tures of schizophrenia, including the presence of Deﬁcit Syndrome. Fur-
thermore, the battery demonstrated an adequate relationship with
patient functional status (i.e., work situation, global disability and spe-
ciﬁc disabilities in daily life) and to have an adequate discriminative ca-
pacity to identify patients with no or a low-moderate global impact on
functional outcomes related to mental health and complementary to
clinician's impression.
The EPICOG-SCH is not a comprehensive battery but a brief one, and
for that reason, it is a good candidate to be included as a screening tool
to explore and monitor cognitive status in regular outpatient follow-up
visits. Although the length of a test battery for evaluating cognitive sta-
tus or changes in clinical settings is not established, there is some con-
sensus that small batteries can be as sensitive as longer ones (Fervaha
et al., 2014a; Hurford et al., 2011; Keefe et al., 2016). It is important to
mention that based onpost hoc analysis of studieswith large study sam-
ples, ultra-brief batteries covering the assessment of the processing
speed and working memory domains are recognized valid and efﬁcient
indicators of overall cognitive functioning in schizophrenia; further-
more these domains are also related to patient functional outcomes
(Fervaha et al., 2014a; Shelton et al., 2009). Subtest selection for the
EPICOG-SCH was guided not only by well-deﬁned assessment objec-
tives but also by existing practical limitations such as the availability
of country normative data and its usability features (in simplicity of ad-
ministration and scoring directions, administration time required, a
need for minimal material, the use of well-known neuropsychological
tasks), among others. Hence, this battery includes key subtests for
schizophrenia such as those mentioned in existing brief or ultra-brief
batteries (i.e., processing speed and working memory such as in the
BNA) and includes themeasurement of Executive Functioning and Verbal
Memory, based on evidence that these domain are related to a patient's
occupational situation or quality of life (Nuechterlein et al., 2008);therefore, the EPICOG-SCH included the CFT and the Immediate LMsub-
test. In summary, the EPICOG-SCHwas not based on a post-hoc analysis
of existing data, but on an ad hoc innovation that addresses a need
that was unmet, when the project started, and it was validated through
a homogenous patient sample in terms of clinical and treatment
stability.
4.1. Relationship to sociodemographic and clinical factors
Similar to the results of other batteries, the EPICOG-SCH showed an
association to sociodemographic factors and, as expected, effects of age
and education level. Regarding gender, differences found at the subtest
level were small and not visible when the performance was combined
in global Composite Scores. This observation in such a large sample sup-
ports the idea that if differences do exist, they are not large. However, in
addition to exploring differences between genders, further data analysis
is needed to explore gender differences in terms of domains rather than
individual subtests or global scores. Past research concluded that
women have speciﬁc advantage in executive functioning (Karilampi et
al., 2011) or even no differences were foundwhen compared to normal
population (Bozikas et al., 2010).
Overall, the Composite Scores were sensitive to the severity of the
patient's clinical symptom proﬁle. When comparing subjects with dif-
ferent symptom severities, we observed that differences on battery per-
formance in both battery Composite Scores ranged from an SES of
−0.56 to−0.87 for larger differences, to an SES 1.20, for the Global Dis-
ease severity subscale when FWCS performance of subjects at the ex-
treme severity categories were compared. It has been broadly
accepted that schizophrenia is associated with cognitive impairment
of approximately 1 SES compared with healthy subjects (Schaefer et
al., 2013). In this regard, our study indicated that similar SES differences
can be found within a sample of schizophrenia patients, with different
degrees of clinical symptom severity. Schaefer et al., 2013 published a
meta-analysis based on data from 100 studies including healthy con-
trols and 9048 people with schizophrenia in which a grand mean effect
size of Hedges g =−1.03 was reported across all cognitive tests when
schizophrenia patients and controls were compared;most measure-by-
measure and domain-level SES values fell within the medium to large
range (−0.63 to−1–11), and larger SES values observed for the DSC
g =−1.55. Other published reviews comparing patients with healthy
subjects, reported SESs ranging from−0.85 for Memory Tasks (Haut
et al., 2015) to −1.55 for the DSC (Heinrichs and Zakzanis, 1998) or
g =−1.21 for the CFT (Schaefer et al., 2013). In our study, SES calcula-
tions and a between-subjects design enabled us to conﬁrm the relation-
ship between studied factors but did not allow for a generalization of
the results (Lakens, 2013). This is because Cohen's d effect size can be in-
ﬂuenced by several factors related to the sample's features such as het-
erogeneity of the studied measures.
The severity of Negative Symptoms and Global Disease was strongly
associated with Verbal Immediate Memory/Working Memory (LM.
LNS) and the severity of Positive Symptoms to Information Processing
Speed (DSC). The association between the severity of Negative Symp-
toms and memory is consistent with results reported by previous re-
searchers (Faerden et al., 2009; Faerden et al., 2013; Roth et al., 2004)
and recently, has been conﬁrmed using reliable tools to assess apathy
dimensions and negative symptoms (Raffard et al., 2016). Factors such
as the emotion toward stimuli novelty during information processing
have been analyzed and were shown to play an important role in
intermediating this relationship. Additionally, the relationship between
“amotivation” and cognition has been extensively explored, and “effort”
has been identiﬁed as the mediator between motivation and cognition
(Fervaha et al., 2014b; Foussias et al., 2015). Despite the existing body
of research in this ﬁeld, the relationship has not yet been described. As
previously suggested, contemporary neuropsychological assessment re-
quires the assessment of other factors thatmay contribute to low cogni-
tive functioning (Harvey, 2012), therefore future research would
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effort associated to each cognitive task and also a measure of reliability
of the evaluation session made by the clinician administering the tests.
The presence of Deﬁcit Syndrome (Kirkpatrick et al., 2000; Arango et
al., 1998; Arango et al., 2004) showed a pattern similar to that of the se-
verity of Negative Symptoms (Verbal Immediate Memory/Working
Memory) but adding a medium effect on Executive performance
(CFT). Overall, the identiﬁed differences were not large, a ﬁnding that
is consistent with previous research indicating that the deﬁcit subtype
of schizophrenia is not markedly distinct from non-deﬁcit schizophre-
nia in terms of neurocognitive performance (Fervaha et al., 2015).
Along these lines, recent research showed that deﬁcit patients tend to
performworse on cognitive tests; however themagnitude of this effect
is relatively modest, translating to over 70% overlap in scores between
groups. However, small differences related to workingmemory and ex-
ecutive functioning might have a substantial impact on functional out-
comes (Zaragoza Domingo et al., 2015). Similar batteries such as
RBANS did not ﬁnd relationship between cognitive performance and
patient clinical symptoms, as measured by BPRS ratings at a short-
term follow-up (Gold et al., 1999) but at a long-term follow-up, greater
psychiatric symptom severity asmeasured by the PANSSwas associated
with lower cognitive performance on speciﬁc indexes (Immediate
Memory and Attention) (Dickerson et al., 2014).
The EPICOG-SCH battery has proven sensitive to clinical proﬁle and
symptom severity; however a causal relationship between these factors
cannot be conﬁrmed by a cross-sectional design study, and prospective
cohort studies are needed. Given our results, we only can hypothesize
that during stable periods of schizophrenia, cognitionmay not be a stat-
ic feature of the disease, and might instead be linked to ﬂuctuations as
symptom severity varies naturally across short periods of time and
therefore co-varies with clinical course. If this hypothesis is conﬁrmed
with prospective cohort studies, it could have important methodologi-
cal implications for clinical trials targeting cognition in schizophrenia.
4.2. Relationship to functional status
The EPICOG-SCH Composite Scores showed a signiﬁcant medium-
to-large relationship to patient functional status in terms of work situa-
tion and disability in daily life as measured by the WHO-DAS-S. Addi-
tionally they showed a large effect on speciﬁc domains such as
Personal Care and Broad Social Functioning and, a moderate effect for Oc-
cupational and Familial Functioning.
In terms of correlations EPICOG-SCH Composite Scores showed
higher correlations with functional measures than individual subtests
did (r=0.44) as expected (Harvey, 2012). In addition to substantial dif-
ferences in measurement methods used, other similar batteries also re-
ported this relationship; higher performance on RBANS was related to
being actively employed (employment time) after controlling for edu-
cational differences (p b 0.01) (Gold et al., 1999), BACS performance
was strongly related to functional measures such as everyday living
skills (r = 0.56) and independent living skills (r = 0.48) (Keefe et al.,
2006); and also differences in MCCB Composite Score results were
found between patients as a function of employment status
(p b 0.05)(August et al., 2012).
The battery's summary global scores provided an overall reliable
index of how well the patient performed in multiple domains affected
in schizophrenia. Generally speaking, although unit-weight Composite
Scores might work well in a number of situations, regression weighted
scores have been showed to be a good solution, in other contexts, for
calculating a battery Composite Score (Bobko et al., 2016). The latter is
a more accurate approach based on maximizing the linear relationship
between the predictors (the cognitive subtest scores) and the predic-
tion of a patient's functional outcome (number of areas of disability/
functionality). In our study, compared to the UCS, the FWCS provided
a more useful summary and consequently performed better in the
ROC analysis in its capacity to relate cognition with a patient'sfunctionality; therefore, the FWCS has a potential application in clinical
practice as complementary information to conﬁrm or predict a patient's
functional outcome.When the battery is used by clinicians, the accuracy
to identify patients with only low-moderate functional disability would
improve in a range of 3 to 7 times at a FWCS cut off ≥ 100. This accuracy
can be understood as the capacity of the battery to help clinicians iden-
tify patients by using an objective measure with only low-moderate
functional impact (potential functional daily life), thereby
complementing the clinical assessment based on interviews. Actually,
this result is not a large improvement per se on diagnostic power, but
a small improvement that can be meaningful from the mental health
standpoint. Along these lines, the information provided by the battery
improves the clinician's accuracy to nearly “good” accuracy to identify
those patients with a Fair Functional status (see Fig. 3).
Our results have some shortcomings arising from the observed im-
balance between sensitivity and speciﬁcity. These shortcomings can
only be compensated, when determining the best cut off score to use
in clinical practice, by analyzing its consequences, for the patient, care-
givers or health system, of an incorrect prognosismadewith thebattery.
Methodologically, increase in speciﬁcity can be achieved by applying
age and education corrections, mainly with adults who are relatively
old or poorly educated. Thismethod ensures that cognitive performance
is isolated from contextual matters so that each individual is viewed in
relation to others based on age, education and gender (Heaton et al.,
1999). However, when using corrected norms, it should be noted that
education in schizophrenia is not always completed on time due to
the natural disease course, consequently correction factors need to be
considered on an individual basis. EPICOG-SCH group is using regres-
sion-based methods to produce corrected norms (van der Elst et al.,
2011; Guardia-Olmos et al., 2015) that will be made available to clini-
cians as the website based tools for calculation of exact Composite
Scores.
4.3. Assessing cognition in clinical practice
In clinical settings, the use of a batterywith available normative data
from both the general population and a disease-speciﬁc population al-
lows for the interpretation of results at two levels: ﬁrst, understanding
a patient's cognitive state compared with that of the reference popula-
tion, and second, understanding cognitive impact of the disease in rela-
tion to other patients with same condition.Within this project, we have
co-normed well-known cognitive subtests, improving the comparison
of different tests administered at the same time and within the same
normative population (Smith and Ivnik, 2003). There is a lack of consen-
sus regarding the bestmethods for assessing cognitive change in clinical
practice, although cognitive impairment is as important as functional
disability as a treatment target. Cognitive measures to be valid need to
have strong test-retest reliability, validity, correlations with functional
outcomes, minimal practice effects, sensitivity to diagnostic differences,
and sensitivity to treatment (intervention) effects. In addition they
should be practical for testers to administer and tolerable for patients
(Keefe et al., 2016).
Similar to other well validated cognitive batteries for schizophrenia,
the EPICOG-SCH battery (1) covers key domains that are commonly re-
ported to be affected in schizophrenia, including processing speed, ex-
ecutive functioning and working memory/verbal memory (other brief
batteries such as RBANS are less speciﬁc while others such as B-BCATS,
BCA or BNA are too brief and do not include all these domains) (2)
can be administered within a medium evaluation time of ~20′ (not as
long as the MCCB which requires 60–90′ and the RBANS or BACS
which require nearly 30′ or more) (3) does not require any extra mate-
rial other than paper and pencil (other batteries such as the BACS or
MCCB require additional items) (4) includes only traditional neuropsy-
chological tasks that are well known by Mental Health professionals
(other batteries such as SCIP or MCCB include some less known tasks)
(5) requires minimal training for evaluators and the guidance included
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to administer and score the battery (other batteries such RBANS, MCCB
require more intensive training).
The EPICOG-SCH approach allows clinicians ﬁrst, to quantify cogni-
tive status at the single subtests and Composite Scores levels useful to
establish a baseline or follow up cognitive measurement; second, to
identify the presence of cognitive impairment (provided that country
normative data from general population exist for each subtest included
in the battery); third, to locate and understand patient performance
within the normative sample of schizophrenia patients (Supplementary
Tables 2–6); and fourth, to use the FWCS to predict the potential impact
of cognition on functional outcomes by considering the cut off as refer-
ence (cut-off b 96). Eventually, setting a baseline for patient's cognitive
performance using the EPICOG-SCH would allow clinicians to monitor
cognition across routine visits and ﬂuctuations across the course of the
disease or in response to therapeutic interventions or drug adjustments.
Future research should address additional features of this battery,
such as test-retest stability over time for frequent measurement. It is
important to highlight that the stability of subtests included in the
EPICOG-SCH battery has been widely described and published else-
where (Lezack et al., 2004; McCaffrey, 2000) and was one of the main
criteria for its inclusion in this battery. Other features such as sensitivity
to diagnostic differences and to intervention effects also need to be con-
ﬁrmed. Furthermore alternative forms should be developed for repeat-
ed measurements over short time intervals.
Regarding limitations, it is important to highlight that the EPICOG-
SCHbattery does not evaluate all the relevant domains in this condition,
i.e., Attention-Vigilance, Visual Learning and Memory, Reasoning and
Problem Solving and Social Cognition, which can be found included in
more comprehensive tools as MCCB. Clinicians who aim to explore
these dimensions need to use a more comprehensive battery because
the EPICOG-SCH does not provide a full picture and covers some of
the cognitive skills affected by this disease; indeed, it is limited to the
above mentioned domains of processing speed, executive functioning
andworkingmemory/verbalmemory. The EPICOG-SCH canbe especial-
ly useful in clinical settings with time constraints; however it does not
provide a complete picture of patient cognitive status or enough infor-
mation to establish cognitive rehabilitation plans. These factors are im-
portant to consider when evaluating our results.
It should be noted that the patients studied in the present paper
were clinically stable and had mild to moderate degrees of severity,
thus compromising the external validity of the results in other popula-
tions of outpatients with more severe schizophrenia. Consequently, to
increase the external validity, a sensitivity analysis that included all pa-
tients in the project (N = 848) will be completed in the future to con-
ﬁrm our ﬁndings and further investigate the effects, in terms of
direction and magnitude, of our observed results when patient hetero-
geneity is increased.4.4. Clinical implications and conclusions
Although other brief and ultra-brief batteries exist, the EPICOG-SCH
successfully achieved its objectives of serving as a brief cognitive battery
that captures cognitive performance related to patients' functional out-
comes in daily living using well-known classical subtests currently
available in a number of countries and languages. The battery has prov-
en to be useful to screen for cognitive impact of schizophrenia with nor-
mative data, and its functional regression-weighted Composite Score is
an efﬁcient complement to routine clinical interviews that aim to con-
ﬁrm patients' potential functional outcomes. Furthermore, this battery
is useful for monitoring cognition during routine outpatient follow-up
visits. Because the calculation method is available and patient-norma-
tive data are presented, the battery is a clinical outcome assessment in-
strument ready to screen cognitive impact and monitor clinically stable
outpatients during maintenance drug or behavioral therapy.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scog.2017.03.001.
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